New Studies Use EHR-based Real-World Evidence To Uncover New Findings on COPD Risk Factors and Patient Characteristics
Researchers from AstraZeneca and Veradigm have published two new studies in the International Journal of Chronic Obstructive Pulmonary Disease leveraging de-identified patient data sourced from a nationwide, electronic health record platform and linked to claims data.
"Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort”, provides the first comprehensive evaluation of blood eosinophil count, healthcare utilization, and cost as reflected in current clinical practice across the United States.
“Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice” is the first study to describe demographic and clinical characteristics, prior treatment patterns, inhaler type, and utilization of healthcare resources in a US patient cohort having initiated long‑acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) fixed-dose combination (FDC) treatment.
To learn more about the specific findings of these studies, download these articles from AstraZeneca and Veradigm now.
GET THE ARTICLES